CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA

References

• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9(5):402–12; PMID:18431400; https://doi.org/10.1038/nrm2395
   PubMed Web of Science ®Google Scholar
• Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: Strategies, Challenges and Opportunities. Curr Drug Targets 2014; 15(1):80–9; PMID:24387333; https://doi.org/10.2174/1389450114666140106101412
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25(3):304–17.
   PubMed Web of Science ®Google Scholar
• Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nat Genet 1993; 4(1):42–6; PMID:8099841; https://doi.org/10.1038/ng0593-42
   PubMed Web of Science ®Google Scholar
• Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119(6):861–72; PMID:15607981; https://doi.org/10.1016/j.cell.2004.11.006
   PubMed Web of Science ®Google Scholar
• Oshima Y, Sasaki Y, Negishi H, Idogawa M, Toyota M, Yamashita T, Wada T, Nagoya S, Kawaguchi S, Yamashita T, et al. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol Ther 2007; 6(7):1058–66; PMID:17568187; https://doi.org/10.4161/cbt.6.7.4320
   PubMed Web of Science ®Google Scholar
• Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A 2006; 103(29):11003–8; PMID:16835297; https://doi.org/10.1073/pnas.0604507103
   PubMed Web of Science ®Google Scholar
• Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Prodigiosin rescues deficient p53 signaling and anti-tumor effects via up-regulating p73 and disrupting its interaction with mutant p53. Cancer Res 2014; 74(4):1153–65; PMID:24247721; https://doi.org/10.1158/0008-5472.CAN-13-0955
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res 2015; 75(18):3842–52; PMID:26294215; https://doi.org/10.1158/0008-5472.CAN-13-1079
   PubMed Web of Science ®Google Scholar
• Vakifahmetoglu-Norberg H. Chaperone-mediated autophagy degrades mutant p53. Genes Dev 2013; 27(15):1718–30; PMID:23913924; https://doi.org/10.1101/gad.220897.113
   PubMed Web of Science ®Google Scholar
• Garufi A. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis 2014; 5:e1271; https://doi.org/10.1038/cddis.2014.217
   PubMed Web of Science ®Google Scholar
• Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2010; 21(5):614–25
   Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8(3):282–8; PMID:11875500; https://doi.org/10.1038/nm0302-282
   PubMed Web of Science ®Google Scholar
• Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011; 18(12):1904–13; PMID:21637290; https://doi.org/10.1038/cdd.2011.71
   PubMed Web of Science ®Google Scholar
• Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol 2015; 5:288; PMID:26732534; https://doi.org/10.3389/fonc.2015.00288
   PubMed Web of Science ®Google Scholar
• North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002; 33(3):181–8; PMID:11870884; https://doi.org/10.1002/mc.10038
   PubMed Web of Science ®Google Scholar
• Mizushima N, Yoshimori T. How to Interpret LC3 Immunoblotting. Autophagy 2007; 3(6):542–5; PMID:17611390; https://doi.org/10.4161/auto.4600
   PubMed Web of Science ®Google Scholar
• Pyo JO. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem 2005; 280(21):20722–9; PMID:15778222; https://doi.org/10.1074/jbc.M413934200
   PubMed Web of Science ®Google Scholar
• Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105(30):10360–165; PMID:18650397; https://doi.org/10.1073/pnas.0805326105
   PubMed Web of Science ®Google Scholar
• Vinod P, Guillermina L. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 2014; 28(16):1739–51; PMID:25128494; https://doi.org/10.1101/gad.247452.114
   PubMed Web of Science ®Google Scholar
• Yousefi S. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8(10):1124–32; PMID:16998475; https://doi.org/10.1038/ncb1482
   PubMed Web of Science ®Google Scholar
• Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, Shimizu S. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009; 461 (7264):654–8; PMID:19794493; https://doi.org/10.1038/nature08455
   PubMed Web of Science ®Google Scholar
• Liu YL. Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget 2014; 5(22):1237–51.
   Web of Science ®Google Scholar
• Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1(1):47–55; https://doi.org/10.4161/cbt.1.1.41
   PubMed Web of Science ®Google Scholar